The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.
The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.
Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.
The two companies have established a broad framework that will enable them to collaborate on specific projects to develop NGS-based companion diagnostics.
The companies will combine MolecularMD's specialty diagnostic assays with Definiens' quantitative tissue read-outs to provide customized diagnostic solutions in oncology.
MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.
The firm's NGS-based Notch 1 mutation detection test will be used to enroll patients in clinical trials.
The NGS laboratory has validated methods and platforms for circulating tumor DNA analysis.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.